[go: up one dir, main page]

MX2017009810A - Derivado de nitroimidazol contra tuberculosis pulmonar. - Google Patents

Derivado de nitroimidazol contra tuberculosis pulmonar.

Info

Publication number
MX2017009810A
MX2017009810A MX2017009810A MX2017009810A MX2017009810A MX 2017009810 A MX2017009810 A MX 2017009810A MX 2017009810 A MX2017009810 A MX 2017009810A MX 2017009810 A MX2017009810 A MX 2017009810A MX 2017009810 A MX2017009810 A MX 2017009810A
Authority
MX
Mexico
Prior art keywords
pulmonary tuberculosis
nitroimidazole derivative
diseases caused
mycobacterium tuberculosis
derivative
Prior art date
Application number
MX2017009810A
Other languages
English (en)
Inventor
Z Ding Charles
Chen Shuhui
ANG Zhigang
Luo Wei
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201610006632.8A external-priority patent/CN106946909A/zh
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of MX2017009810A publication Critical patent/MX2017009810A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente se revela un derivado sustituido de nitroimidazol, que se utiliza principalmente para el tratamiento de enfermedades relacionadas causadas por infecciones con mycobacterias, tales como Mycobacterium tuberculosis, siendo especialmente adecuado para las enfermedades causadas por variantes resistentes de Mycobacterium tuberculosis.
MX2017009810A 2015-01-29 2016-01-28 Derivado de nitroimidazol contra tuberculosis pulmonar. MX2017009810A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510048040 2015-01-29
CN201610006632.8A CN106946909A (zh) 2016-01-06 2016-01-06 抗肺结核病的硝基咪唑衍生物
PCT/CN2016/072447 WO2016119706A1 (zh) 2015-01-29 2016-01-28 抗肺结核病的硝基咪唑衍生物

Publications (1)

Publication Number Publication Date
MX2017009810A true MX2017009810A (es) 2018-11-09

Family

ID=56542438

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009810A MX2017009810A (es) 2015-01-29 2016-01-28 Derivado de nitroimidazol contra tuberculosis pulmonar.

Country Status (10)

Country Link
US (1) US10227362B2 (es)
EP (1) EP3252059A4 (es)
JP (1) JP6542900B2 (es)
CN (1) CN107207532B (es)
BR (1) BR112017015744A2 (es)
MX (1) MX2017009810A (es)
RU (1) RU2675622C1 (es)
TW (1) TW201632533A (es)
WO (1) WO2016119706A1 (es)
ZA (1) ZA201705362B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019104974A (ru) * 2016-07-22 2020-08-24 Медшайн Дискавери Инк. Кристалл и соль нитроимидазола и способ их изготовления
US10971760B2 (en) 2018-01-31 2021-04-06 Keracel, Inc. Hybrid solid-state cell with a sealed anode structure
US11958818B2 (en) * 2019-05-01 2024-04-16 Boehringer Ingelheim International Gmbh (R)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
CN113603706A (zh) * 2021-08-04 2021-11-05 深圳市泰力生物医药有限公司 德拉马尼的晶型、含有该晶型的活性药物和药物组合物
KR20240122521A (ko) 2021-12-14 2024-08-12 베링거 인겔하임 인터내셔날 게엠베하 만성 신장 질환 치료용 알도스테론 신타아제 억제제
WO2023237580A1 (en) * 2022-06-07 2023-12-14 Institut National De La Sante Et De La Recherche Medicale Tricyclic spirolactam compounds with antimycobacterial activity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
US6087358A (en) 1995-06-26 2000-07-11 Pathogenesis Corporation Nitro-[2,1-b]imidazopyran compounds and antibacterial uses thereof
TWI347946B (en) 2002-10-11 2011-09-01 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound
ATE410430T1 (de) 2003-10-31 2008-10-15 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
JP4761756B2 (ja) 2003-10-31 2011-08-31 大塚製薬株式会社 ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物
ZA200602184B (en) * 2003-10-31 2007-10-31 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazo (2,1-B) oxazole compounds for the treatment of tuberculosis
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
BRPI0620251A2 (pt) 2005-12-23 2011-11-08 Us Dept Of Health compostos de nitroimidazol
US7678791B2 (en) 2006-07-12 2010-03-16 Cumbre Ip Ventures, L.P. Nitroheteroaryl-containing rifamycin derivatives
AR070301A1 (es) 2007-05-08 2010-03-31 Otsuka Pharma Co Ltd Compuesto epoxi y metodo para producir el mismo
JP5613656B2 (ja) 2008-03-26 2014-10-29 グローバル、アライアンス、フォア、ティービー、ドラッグ、ディベロップメント 置換されたフェニルオキサゾリジノンと共有結合した二環式ニトロイミダゾール
CA2769263C (en) 2009-07-31 2017-03-07 Global Alliance For Tb Drug Development Nitroimidazooxazine and nitroimidazooxazole analogues and their uses
EP2459571B1 (en) 2009-07-31 2015-03-11 Global Alliance For Tb Drug Development Nitroimidazooxazines and their uses in anti-tubercular therapy
WO2011087995A2 (en) 2010-01-13 2011-07-21 Clifton Barry Organic compounds
TW201200523A (en) 2010-01-29 2012-01-01 Otsuka Pharma Co Ltd Synthetic intermediate of oxazole compound and method for producing the same
GB201012209D0 (en) 2010-05-31 2010-09-08 Ge Healthcare Ltd In vivo imaging agent
EP2697232B1 (en) * 2011-04-15 2016-05-18 Otsuka Pharmaceutical Co., Ltd. 6,7-dihydroimidazo[2,1-b][1,3]oxazine bactericides
WO2013072903A1 (en) 2011-11-17 2013-05-23 Ithemba Pharmaceuticals (Proprietary) Limited Nitroimidazoxadiazocine compounds

Also Published As

Publication number Publication date
BR112017015744A2 (pt) 2018-03-13
TW201632533A (zh) 2016-09-16
ZA201705362B (en) 2019-06-26
EP3252059A1 (en) 2017-12-06
CN107207532A (zh) 2017-09-26
US10227362B2 (en) 2019-03-12
CN107207532B (zh) 2019-07-30
US20180162878A1 (en) 2018-06-14
WO2016119706A1 (zh) 2016-08-04
JP6542900B2 (ja) 2019-07-10
JP2018503658A (ja) 2018-02-08
RU2675622C1 (ru) 2018-12-21
EP3252059A4 (en) 2018-07-11

Similar Documents

Publication Publication Date Title
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
CL2016002157A1 (es) Anticuerpos anti-cd38 para el tratamiento de leucemia linfoide aguda
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
TW201613872A (en) IRAK4 inhibiting agents
MX2017009810A (es) Derivado de nitroimidazol contra tuberculosis pulmonar.
PH12017502237B1 (en) Nuclear receptor modulators
MX2020008507A (es) Metodo para producir 1,1,3,3-tetracloropropeno.
PH12016502003B1 (en) Novel bacteriophage and composition containing same
PH12016501999A1 (en) Novel bacteriophage and composition containing same
AU2016362202A8 (en) Method for preventing or treating nosocomial pneumonia
WO2018116195A3 (en) A method for manufacturing a thermally treated steel sheet
PL3450087T3 (pl) Układ przeciwprzesuwny do pozycjonerów rolkowych
PH12018500903A1 (en) Pyranodipyridine compound
MX2018002354A (es) Métodos para el tratamiento de una enfermedad poliquística renal.
CL2019001526A1 (es) Métodos para el tratamiento de la enfermedad renal poliquística.
MX2017011454A (es) Procesos para preparar fluorocetólidos.
BR112017002139A2 (pt) ?método para preparar um composto?
MX379401B (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
MX2019007174A (es) Metodo para fabricar una lamina de acero tratada termicamente.
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
MX2019004024A (es) Metodo para preparar acetofenonas sustituidas con ciclopropilo.
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
CL2018000489A1 (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
PH12020550958A1 (en) Method for producing carbodiimides
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона